SRR1367128
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.461
- PANCREAS_BETA_CELLS+0.398
- ANGIOGENESIS+0.333
- APICAL_SURFACE+0.288
- ALLOGRAFT_REJECTION+0.263
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.258
- INFLAMMATORY_RESPONSE+0.242
- ESTROGEN_RESPONSE_LATE+0.240
- TNFA_SIGNALING_VIA_NFKB+0.238
- MYOGENESIS+0.221
Top 10 suppressed
- MYC_TARGETS_V2-0.562
- MYC_TARGETS_V1-0.506
- DNA_REPAIR-0.493
- PROTEIN_SECRETION-0.443
- UNFOLDED_PROTEIN_RESPONSE-0.435
- E2F_TARGETS-0.388
- MITOTIC_SPINDLE-0.374
- G2M_CHECKPOINT-0.343
- OXIDATIVE_PHOSPHORYLATION-0.324
- MTORC1_SIGNALING-0.284
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1353221 | GTEX | — | 0.955 |
| 2 | SRR1476571 | GTEX | — | 0.945 |
| 3 | SRR1330346 | GTEX | — | 0.944 |
| 4 | SRR602839 | GTEX | — | 0.939 |
| 5 | SRR1797250 | — | cohortMD2 | 0.936 |
| 6 | SRR1315145 | GTEX | — | 0.934 |
| 7 | MNG1146 | — | — | 0.933 |
| 8 | SRR1392725 | GTEX | — | 0.931 |
| 9 | SRR1317853 | GTEX | — | 0.930 |
| 10 | SRR934982 | — | — | 0.927 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.461 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.398 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.333 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.288 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.263 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.258 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.242 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.238 | Inavolisib | — uncovered |
| MYOGENESIS | 0.221 | Inavolisib | — uncovered |
| COAGULATION | 0.206 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.157 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.146 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.122 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.115 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.080 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.064 | Inavolisib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |